Walk through the marketing for Aviv Clinics and you will read the words "proven," "reverse aging," and "Holy Grail." Walk through the actual peer-reviewed evidence and you will find a single 2020 study of 35 adults over three months. The gap between those two pictures is the subject of this piece — and the reason you should read any Aviv-attributed claim with a careful eye.
This is not an attack on Aviv. The company conducts real research at the Sagol Center for Hyperbaric Medicine and Research in Israel. Its protocols are published in journals. Its investigators have legitimate credentials. The problem is what happens between the study and the headline.
If you are paying $40,000-$50,000 cash for a 60-session anti-aging protocol — which is the price range patients describe in recent Reddit threads on r/HBOT — you should know exactly what the evidence says and where it stops.
The 2020 study that started it all
In November 2020, a research team led by Dr. Shai Efrati published a paper in Aging. The headline finding was striking: "Hyperbaric oxygen therapy increases telomere length and decreases immunosenescence in isolated blood cells: a prospective trial."
The design was prospective and uncontrolled. Thirty-five healthy adults aged 64 and older went through 60 sessions of HBOT over three months at 2.0 atmospheres absolute (ATA) for 90 minutes each, five days a week. The researchers measured telomere length in peripheral blood mononuclear cells (PBMCs) and senescent cell counts before and after the protocol.
The results: telomeres in CD8+ T cells lengthened by 38%, and the percentage of senescent T-helper cells dropped by 37%.
That's the study. Let's be precise about what it is and isn't.
What the 2020 study did show
- A statistically significant change in telomere length in isolated blood cells across the 60-session protocol
- A reduction in senescent cell populations in the same blood samples
- Tolerability of the protocol in this cohort
What the 2020 study did not show
- That biological aging was "reversed" — telomere length is a biomarker associated with cellular aging, not aging itself
- That longevity outcomes were affected — the follow-up was three months
- That the effect persists after stopping treatment — no longer-term measurements were taken
- That the same effects occur outside this exact protocol (2.0 ATA, 90 min, 60 sessions)
- That benefit extends to people younger than 64 or to specific clinical conditions
- That HBOT outperforms other interventions — there was no control arm
The original paper itself is restrained. It calls for "future randomized controlled trials." It frames the work as exploratory. The senior authors emphasize that the markers measured are not synonymous with aging itself.
That restraint did not survive the press cycle.
How "exploratory" became "proven"
In the 90 days following publication, the study became the subject of an extensive coordinated media push. Uproar PR, a Florida-based agency, has publicly documented its work for Aviv Clinics as a case study on its own site. The agency claims credit for the placement of over 400 press pieces about Aviv and the underlying research.
The 400 figure is verifiable in the broader strokes. A simple Google News search for "Aviv Clinics anti-aging" returns hundreds of articles across 2021-2024, ranging from outlets as varied as the New York Post and Newsweek to syndicated wire stories carried by hundreds of local affiliates. Many run nearly identical copy and quotes — a hallmark of a press-release-driven cycle.
The pattern in those pieces is consistent. The 35-person study becomes "research," then "the study," then "trials." The PBMC telomere measurement becomes "biological aging." The 90-day post-protocol measurement becomes "lasting reversal." And the protocol's price — which exceeds $40,000 — is mentioned briefly if at all.
The Aviv blog itself runs headlines like "For the First Time, Hyperbaric Oxygen Therapy Proven to Reverse Biological Aging in Humans." The word "proven" is doing a tremendous amount of work in that headline that the underlying paper does not support.
This is not a fringe pattern in wellness marketing. It is the well-documented dynamic where preliminary research is converted, via PR amplification, into consumer-facing certainty. What makes the Aviv case worth dissecting is the price tag attached.
What the FDA actually says about HBOT for anti-aging
The U.S. Food and Drug Administration maintains a list of HBOT indications it has approved. As of 2026 there are 14, the standard UHMS-recognized set: decompression sickness, carbon monoxide poisoning, gas gangrene, crush injury, decompression illness, arterial gas embolism, severe anemia, thermal burns, intracranial abscess, necrotizing soft tissue infections, osteomyelitis, delayed radiation injury, compromised skin grafts, and idiopathic sudden sensorineural hearing loss.
Anti-aging is not on that list. Neither is cognitive enhancement, biological-age reversal, or "longevity."
The FDA has actively warned consumers about off-label HBOT marketing. In 2021 the agency reissued a public warning that read in part: "Hyperbaric oxygen therapy has not been proven to be the kind of universal treatment it has been touted to be on some Internet sites." The warning specifically called out anti-aging claims as among those the agency does not endorse.
Aviv Clinics is not deceiving regulators here. The company does not claim FDA approval for its anti-aging protocols. But "investigational, off-label, not FDA-approved" is rarely how the marketing actually reads.
Replication: what we still do not know
The most important question about any single trial is whether independent investigators, using the same protocol on similar patients, get the same result.
For the Aviv anti-aging finding, the honest answer is: we do not yet know. As of mid-2026:
- The original Efrati cohort study has not been replicated in a comparable design by an independent group with a control arm.
- A small number of follow-up papers from the Shamir Medical Center group have explored related questions (long COVID cognition, post-stroke recovery, fibromyalgia) — these are interesting but do not address the anti-aging claim directly.
- Other research groups have not converged on the same telomere/senescence effect, in part because few have run the precise 60-session protocol.
Replication is not a luxury in biomedical research. It is the floor. A single study, no matter how well-designed, is the start of a research program — not the conclusion of one.
The fairest summary is this: the 2020 study is interesting preliminary evidence that 60 sessions of 2.0 ATA HBOT may affect specific blood biomarkers associated with cellular aging in older adults. Whether that translates to longer healthspan, reduced disease, or any patient-perceptible benefit is a question the field has not yet answered.
A patient considering $40,000 of cash treatment should know this.
What does happen in the chamber, and what likely doesn't
To be clear about where I am willing to be specific: HBOT at clinically meaningful pressures (1.5+ ATA in a sealed environment with 100% oxygen) does produce measurable physiological effects. Tissue oxygen tension rises substantially. Vasoconstriction occurs. Inflammatory pathways shift. New capillary growth (angiogenesis) is documented. These are the mechanisms behind the FDA-approved uses, especially wound healing and radiation injury.
What is much less clear:
- Whether the same physiological effects produce population-level anti-aging benefits in healthy older adults
- Whether the effect sizes documented in lab biomarkers translate to outcomes patients can perceive — energy, cognitive function, life expectancy
- Whether the benefits, if real, persist after stopping treatment or require lifelong maintenance
- Whether the off-label use of HBOT carries adequate safety margins when administered for non-FDA indications (the safety database is built primarily on FDA-approved-condition data)
The honest stance is this: there is good reason to believe HBOT does something to the human body at hyperbaric pressures. There is not yet good reason to believe that something amounts to "reversing aging" in any colloquial sense.
How to read an Aviv claim — and any HBOT marketing
A short checklist for evaluating the language you will encounter:
-
Does the claim cite a specific study? Demand the citation. If it's "research shows…" without a paper, treat as marketing.
-
Is the study controlled? A prospective cohort with no comparison arm cannot tell you HBOT outperforms doing nothing. An RCT can. Anti-aging research has not yet produced an HBOT RCT.
-
What was the sample size? Thirty-five is small. Three thousand is meaningful. Smaller studies require replication to count.
-
What did the study actually measure? Telomere length in blood cells is a biomarker. "Biological age" in headlines often refers to that biomarker, not a meaningful clinical outcome.
-
Is the protocol disclosed? 60 sessions at 2.0 ATA for 90 minutes each is the published protocol. Many wellness clinics offering "Aviv-style" treatment use shorter protocols at lower pressures — those have not been studied.
-
Is the FDA status acknowledged? Off-label is not illegal, but it is medically meaningful. Patients deserve to know.
-
Is the price disclosed transparently? Reputable medical providers publish protocol costs. Cash-pay-only wellness clinics often do not.
-
Is the source of the claim financially conflicted? A clinic citing its own research is not in itself disqualifying, but it raises the bar for independent verification.
The legitimate parts of Aviv's work
It would be unfair to end here without noting what the Aviv team has done well.
The Sagol Center is a real research operation. The investigators have published in indexed journals. They are willing to disclose protocols in technical detail. They do not, to my knowledge, claim FDA approval they do not have. They have studied conditions with serious unmet need — long COVID, post-stroke cognition, fibromyalgia — and produced findings worth replicating. The senior author, Dr. Shai Efrati, has been responsive to scientific criticism in published correspondence.
The problem is not the underlying research. The problem is the gap between the research and the marketing layer that surrounds it.
A patient who reads the original Efrati 2020 paper will come away with calibrated uncertainty. A patient who reads the press cycle that followed will come away with a sense of established fact. Those two patients walk into the same clinic and pay the same price — but only one of them knows what they are buying.
What to do if you are considering an Aviv-style protocol
-
Read the original 2020 paper yourself. It's open-access in Aging. Page through the methods, not just the abstract. Note what was and was not measured.
-
Ask your provider for specific replication data. "Has this protocol been replicated by independent investigators with a control arm?" If the answer is no, that is meaningful.
-
Treat the protocol as investigational. Frame your expectations as: this might help, this might do nothing measurable, the evidence is preliminary.
-
Don't pay more than you can afford to lose. Cash-pay protocols at $40,000+ are not refundable when the promised effect doesn't materialize.
-
Look for FDA-cleared facilities. Our UHMS-accredited clinic directory tracks facilities operating under standard medical oversight. UHMS accreditation is not a guarantee of effectiveness for off-label uses, but it is a baseline credibility signal.
-
Consider a second opinion from a physician without a financial stake in HBOT. A primary care doctor or specialist treating your underlying condition is in a better position to weigh tradeoffs than the staff at the clinic selling the protocol.
Sources and further reading
- Hachmo Y, Hadanny A, Abu Hamed R, et al. Hyperbaric oxygen therapy increases telomere length and decreases immunosenescence in isolated blood cells: a prospective trial. Aging (Albany NY). 2020;12(22):22445-22456.
- U.S. Food and Drug Administration. Hyperbaric Oxygen Therapy: Get the Facts. Consumer Updates, 2021.
- Undersea and Hyperbaric Medical Society. Indications for Hyperbaric Oxygen Therapy.
- Uproar PR. Aviv Clinics case study. (Documents the agency's media-placement work.)
- Aviv Clinics. Brain Health blog. (For the company's own positioning, in their own words.)
Frequently asked questions
Is Aviv Clinics a scam? No, not in any legal or technical sense. The clinics are licensed medical facilities providing real HBOT under physician supervision. The criticism here is about the marketing of off-label, investigational uses — not the existence of the treatment itself. The chambers are real. The physiological effects are real. What is in dispute is what those effects mean for healthy adults seeking "anti-aging."
Has the 2020 telomere study been replicated? Not as of mid-2026, to the best of my knowledge. The Shamir Medical Center group has published related work in other indications, but no independent group has reproduced the specific anti-aging finding with a controlled design. This is a known gap in the literature.
Is HBOT FDA-approved for anti-aging? No. The FDA has approved HBOT for 14 specific indications, none of which are anti-aging, longevity, or biological-age reversal. Use for those purposes is off-label. The FDA has issued public warnings specifically about off-label HBOT marketing claims.
Why does the marketing differ so much from the original research? The original paper is restrained in tone — the senior authors acknowledge limitations and call for further research. The marketing layer around it (press releases, social media, blog content) reframes the same finding in much stronger terms. This is a common pattern in wellness-industry marketing, not unique to Aviv. The 400+ press placements documented by the company's PR agency are a measurable expression of how much amplification a single study can receive.
Should I avoid HBOT entirely because of these concerns? No. HBOT has 14 FDA-approved indications where the evidence is solid and the benefit is documented — wound care, decompression sickness, radiation injury, and others. The criticism here is specifically about off-label anti-aging marketing, not the therapy itself. If you have a covered indication, HBOT may be entirely appropriate. If you are paying cash for an off-label protocol, calibrate your expectations to the actual evidence.
Medical disclaimer: This article is for informational purposes only and does not constitute medical advice. Hyperbaric oxygen therapy carries genuine risks — barotrauma, oxygen toxicity, fire safety — and should only be administered in appropriately equipped facilities under medical supervision. Consult a physician before pursuing any HBOT protocol. The information here reflects published research as of 2026; the field is active and new evidence may change the picture.
— The HBOT Finder Team